Abstract:Background: Diabetic kidney disease (DKD) is the most common cause of the end-stage renal disease (ESRD). Regardless of intensive treatments with hyperglycemic control, blood pressure control, and the use of renin-angiotensin system blockades, the prevalence of DKD remains high. Recent studies suggest that the spectrum of DKD has been changed and many progresses have been made to develop new treatments for DKD. Therefore, it is time to perform a systemic review on the new developments in the field of DKD. Summary: Although the classic clinical presentation of DKD is characterized by a slow progression from microalbuminuria to macroalbuminuria and by a hyperfiltration at the early stage and progressive decline of renal function at the late stage, recent epidemiological studies suggest that DKD patients have a variety of clinical presentations and progression rates to ESRD. Some DKD patients have a decline in renal function without albuminuria but display prominent vascular and interstitial fibrosis on renal histology. DKD patients are more susceptible to acute kidney injury, which might contribute to the interstitial fibrosis. A large portion of type 2 diabetic patients with albuminuria could have overlapping nondiabetic glomerular disease, and therefore, kidney biopsy is required for differential diagnosis for these patients. Only a small portion of DKD patients eventually progress to end-stage renal failure. However, we do not have sensitive and specific biomarkers to identify these high-risk patients. Genetic factors that have a strong association with DKD progression have not been identified yet. A combination of circulating tumor necrosis factor receptor (TNFR)1, TNFR2, and kidney injury molecular 1 provides predictive value for DKD progression. Artificial intelligence could enhance the predictive values for DKD progression by combining the clinical parameters and biological markers. Sodium-glucose cotransporter-2 inhibitors should be added to the new standard care of DKD patients. Several promising new drugs are in clinical trials. Key Messages: Over last years, our understanding of DKD has been much improved and new treatments to halt the progression of DKD are coming. However, better diagnostic tools, predictive markers, and treatment options are still urgently needed to help us to better manage these patients with this detrimental disease. (C) 2020 The Author(s) Published by S. Karger AG, Basel

Some problems in hemodialysis in patients with diabetics end-stage renal disease

Selection of dialysis methods for end-stage kidney disease patients with diabetes

Challenges in Management of Diabetic Patient on Dialysis

The Nephrologist's Role in the Collaborative Multi-Specialist Network Taking Care of Patients with Diabetes on Maintenance Hemodialysis: An Overview

Renal Replacement Therapy for End-Stage Diabetic Nephropathy

What is the optimal dialysis method for diabetic patients with end stage kidney disease?

Diabetic Kidney Disease: Challenges, Advances, And Opportunities

Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases

Ion homeostasis in diabetic kidney disease

Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Comparison of Peritoneal Dialysis with Hemodialysis on Survival of Diabetic Patients with End-Stage Kidney Disease: a Meta-Analysis of Cohort Studies

Diabetic Nephropathy: An Overview

Diabetes mellitus and renal failure effect on intestinal insulin

Management of diabetes in people with advanced chronic kidney disease

Therapeutic Advances in Diabetic Nephropathy

Prevention and treatment of diabetic nephropathy: a long way to go

Clinical Research of Peritoneal Dialysis in Patients with ESRD

Progress of Research on Mortality Risk Factors in Elderly Patients Undergoing Maintenance Hemodialysis

A study on the epidemiologic characteristics of paients with end stage renal disease undergoing hemodialysis

New Approaches to Diabetic Nephropathy from Bed to Bench

The Role of the Gut Microbiota in Complications among Hemodialysis Patients